Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Schizophrenia

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 89 articles:
HTML format



Single Articles


    January 2024
  1. PEREZ-ROMERO N, Campos-Jara C, Pesce C, Araya Sierralta S, et al
    Effects of physical exercise on executive functions of individuals with schizophrenia spectrum disorders: Protocol for a systematic review and meta-analysis.
    PLoS One. 2024;19:e0296273.
    PubMed     Abstract available


  2. CLEMMENSEN L, Lund CN, Andresen BS, Midtgaard J, et al
    Study protocol for RUFUS-A randomized mixed methods pilot clinical trial investigating the relevance and feasibility of rumination-focused cognitive behavioral therapy in the treatment of patients with emergent psychosis spectrum disorders.
    PLoS One. 2024;19:e0297118.
    PubMed     Abstract available


  3. JAKA S, Singh S, Vashist S, Pokhrel S, et al
    Pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: Exploring psychosis, related risk factors, and hospital outcomes in a nationwide inpatient sample: A cross-sectional study.
    PLoS One. 2024;19:e0296870.
    PubMed     Abstract available


  4. ROSADO D, Intriago B, Loor E, Alcivar F, et al
    Associations between Toxoplasma gondii seropositivity and psychopathological manifestations in schizophrenic patients: A single-center study from Ecuador.
    PLoS One. 2024;19:e0297523.
    PubMed     Abstract available


  5. FEIJS HME, van Aken L, van der Veld WM, van der Heijden PT, et al
    No relations between executive functions and dimensional models of psychopathology or is time the missing link?
    PLoS One. 2024;19:e0288386.
    PubMed     Abstract available



  6. Expression of Concern: Synaptic Dysbindin-1 Reductions in Schizophrenia Occur in an Isoform-Specific Manner Indicating Their Subsynaptic Location.
    PLoS One. 2024;19:e0301152.
    PubMed    


  7. LIU J, Sun SJ, Lu Y, Ping X, et al
    Taste dysfunction as a predictor of depression in schizophrenia: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0300935.
    PubMed     Abstract available


  8. BASU A, Dutta AK, Bagepally BS, Das S, et al
    Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers.
    PLoS One. 2024;19:e0300511.
    PubMed     Abstract available


    January 2023
  9. LI S, Otsuka I, Tanifuji T, Okazaki S, et al
    Ribosomal DNA gene copies are increased in blood and brain of Japanese schizophrenia patients.
    PLoS One. 2023;18:e0280694.
    PubMed     Abstract available


  10. BYRNE MK, Easpaig BNG, Gray R, Creek R, et al
    Behavioural activation for depressive symptoms in young people with emerging or early psychosis: A pilot study protocol.
    PLoS One. 2023;18:e0280559.
    PubMed     Abstract available


  11. LONGARDNER K, Wright BA, Alakkas A, You H, et al
    Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
    PLoS One. 2023;18:e0278262.
    PubMed     Abstract available


  12. COHEN LS, Vanderkruik R, Arakelian M, Church TR, et al
    Establishment of the MGH Postpartum Psychosis Project: MGHP3.
    PLoS One. 2023;18:e0281133.
    PubMed     Abstract available


  13. MIDDLETON CURRAN L, Sheridan Rains L, Taylor J, Morant N, et al
    Acceptability and feasibility of using contingency management for cannabis reduction in specialist mental health services for psychosis: A qualitative study of staff views.
    PLoS One. 2023;18:e0281368.
    PubMed     Abstract available


  14. HANCOCK F, Rosas FE, McCutcheon RA, Cabral J, et al
    Metastability as a candidate neuromechanistic biomarker of schizophrenia pathology.
    PLoS One. 2023;18:e0282707.
    PubMed     Abstract available


  15. FEI X, Wang S, Li J, Wang J, et al
    The efficacy and safety of sodium nitroprusside in the treatment of schizophrenia: Protocol for an updated systematic review and meta-analysis.
    PLoS One. 2023;18:e0283185.
    PubMed     Abstract available


  16. XAVIER RM, Shanavas Y, Britt BM, George WT, et al
    Influences of race and clinical variables on psychiatric genetic research participation: Results from a schizophrenia sample.
    PLoS One. 2023;18:e0284356.
    PubMed     Abstract available


  17. XU F, Xian Z
    Study investigating executive function in schizophrenia patients and their unaffected siblings.
    PLoS One. 2023;18:e0285034.
    PubMed     Abstract available


  18. RAJAGOPALAN A, Lim KWK, Tan XW, Martin D, et al
    Predictors of cognitive changes in patients with schizophrenia undergoing electroconvulsive therapy.
    PLoS One. 2023;18:e0284579.
    PubMed     Abstract available


  19. MIZUTANI R, Saiga R, Yamamoto Y, Uesugi M, et al
    Structural aging of human neurons is opposite of the changes in schizophrenia.
    PLoS One. 2023;18:e0287646.
    PubMed     Abstract available


  20. ROTENBERG M, Gozdyra P, Anderson KK, Kurdyak P, et al
    The role of geography and distance on physician follow-up after a first hospitalization with a diagnosis of a schizophrenia spectrum disorder: A retrospective population-based cohort study in Ontario, Canada.
    PLoS One. 2023;18:e0287334.
    PubMed     Abstract available


  21. SASAKI J, Muranaka S, Arahata K, Sato A, et al
    Developing and validating the Japanese version of the Referential Thinking Scale: A cross-sectional study.
    PLoS One. 2023;18:e0283416.
    PubMed     Abstract available


  22. GUNDOGMUS AG, Gerretsen P, Song J, Erdi Akdag F, et al
    Insight in schizophrenia is associated with psychoeducation and social support: Testing a new more comprehensive insight tool in Turkish schizophrenia patients.
    PLoS One. 2023;18:e0288177.
    PubMed     Abstract available


  23. ISLAM MK, Islam MR, Rahman MH, Islam MZ, et al
    Integrated bioinformatics and statistical approach to identify the cmmon mlecular mchanisms of oesity that are linked to the development of two psychiatric disorders: Schizophrenia and major depressive disorder.
    PLoS One. 2023;18:e0276820.
    PubMed     Abstract available


  24. CANESSA N, Iozzino L, Andreose S, Castelletti L, et al
    RISK aversion in Italian forensic and non-forensic patients with schizophrenia spectrum disorders.
    PLoS One. 2023;18:e0289152.
    PubMed     Abstract available


  25. MONTAZERI M, Moradi E, Moosazadeh M, Hosseini SH, et al
    Relationship between Toxoplasma gondii infection and psychiatric disorders in Iran: A systematic review with meta-analysis.
    PLoS One. 2023;18:e0284954.
    PubMed     Abstract available


  26. TAMENE FB, Sema FD, Sendekie AK
    Antipsychotic polypharmacy and associated factors among patients with schizophrenia: Multicenter cross-sectional study in Northwest Ethiopia.
    PLoS One. 2023;18:e0290037.
    PubMed     Abstract available


  27. RANDHAWA A, Kuhn S, Schottle D, Moritz S, et al
    The effects of assessing character strengths vs. psychopathology on mood, hope, perceived stigma and cognitive performance in individuals with psychosis.
    PLoS One. 2023;18:e0289872.
    PubMed     Abstract available


  28. CHAVES MF, Rodrigues C, Ribeiro S, Mota NB, et al
    Grammatical impairment in schizophrenia: An exploratory study of the pronominal and sentential domains.
    PLoS One. 2023;18:e0291446.
    PubMed     Abstract available


  29. AGARWAL SM, Dissanayake J, Agid O, Bowie C, et al
    Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol.
    PLoS One. 2023;18:e0288354.
    PubMed     Abstract available


  30. MARTZOUKOU M, Papadopoulos D, Kosmidis MH
    Syntactic and affective prosody recognition: Schizophrenia vs. Autism spectrum disorders.
    PLoS One. 2023;18:e0292325.
    PubMed     Abstract available


  31. JUCHNOWICZ D, Dzikowski M, Rog J, Waszkiewicz N, et al
    The usefulness of a complete blood count in the prediction of the first episode of schizophrenia diagnosis and its relationship with oxidative stress.
    PLoS One. 2023;18:e0292756.
    PubMed     Abstract available


  32. LYLES S, Khan Z, Qureshi O, Shaikh M, et al
    A systematic review of the effectiveness and implementation readiness of psychosocial interventions for psychosis in South Asia.
    PLoS One. 2023;18:e0283411.
    PubMed     Abstract available


  33. CLEMENTI L, Arnone E, Santambrogio MD, Franceschetti S, et al
    Anatomically compliant modes of variations: New tools for brain connectivity.
    PLoS One. 2023;18:e0292450.
    PubMed     Abstract available


  34. ABDIN E, Seet V, Jeyagurunathan A, Tan SC, et al
    Validation of the 12-item World Health Organization Disability Assessment Schedule 2.0 in individuals with schizophrenia, depression, anxiety, and diabetes in Singapore.
    PLoS One. 2023;18:e0294908.
    PubMed     Abstract available


  35. LAWRIE S, Hanlon C, Manda-Taylor L, Knapp M, et al
    Psychosis Recovery Orientation in Malawi by Improving Services and Engagement (PROMISE) protocol.
    PLoS One. 2023;18:e0293370.
    PubMed     Abstract available


    January 2022
  36. ADJORLOLO S, Mensah G, Badzi CD
    Psychosis risk among pregnant women in Ghana.
    PLoS One. 2022;17:e0263011.
    PubMed     Abstract available


  37. ABED-ESFAHANI P, Darwin BC, Howard D, Wang N, et al
    Evaluation of deep convolutional neural networks for in situ hybridization gene expression image representation.
    PLoS One. 2022;17:e0262717.
    PubMed     Abstract available


  38. DHUNGANA S, Tulachan P, Chapagai M, Pant SB, et al
    Internalized stigma in patients with schizophrenia: A hospital-based cross-sectional study from Nepal.
    PLoS One. 2022;17:e0264466.
    PubMed     Abstract available


  39. OKAZAKI S, Boku S, Watanabe Y, Otsuka I, et al
    Polymorphisms in the hypoxia inducible factor binding site of the macrophage migration inhibitory factor gene promoter in schizophrenia.
    PLoS One. 2022;17:e0265738.
    PubMed     Abstract available


  40. JIANG Z, Luskus M, Seyedi S, Griner EL, et al
    Utilizing computer vision for facial behavior analysis in schizophrenia studies: A systematic review.
    PLoS One. 2022;17:e0266828.
    PubMed     Abstract available


  41. SARIS IMJ, Aghajani M, Jongs N, Reus LM, et al
    Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimer's disease patients.
    PLoS One. 2022;17:e0263769.
    PubMed     Abstract available


  42. LIAN L, Kim DD, Procyshyn RM, Cazares D, et al
    Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
    PLoS One. 2022;17:e0267808.
    PubMed     Abstract available


  43. TOYAMA M, Takasaki Y, Branko A, Kimura H, et al
    Exome sequencing of Japanese schizophrenia multiplex families supports the involvement of calcium ion channels.
    PLoS One. 2022;17:e0268321.
    PubMed     Abstract available


  44. ALGUMAEI AH, Algunaid RF, Rushdi MA, Yassine IA, et al
    Feature and decision-level fusion for schizophrenia detection based on resting-state fMRI data.
    PLoS One. 2022;17:e0265300.
    PubMed     Abstract available


  45. FAULKNER SM, Drake RJ, Ogden M, Gardani M, et al
    A mixed methods expert opinion study on the optimal content and format for an occupational therapy intervention to improve sleep in schizophrenia spectrum disorders.
    PLoS One. 2022;17:e0269453.
    PubMed     Abstract available


  46. ERSHOVA ES, Shmarina GV, Martynov AV, Zakharova NV, et al
    NADPH-oxidase 4 gene over-expression in peripheral blood lymphocytes of the schizophrenia patients.
    PLoS One. 2022;17:e0269130.
    PubMed     Abstract available


  47. ADEME M, Kebede T, Teferra S, Alemayehu M, et al
    Is latent Toxoplasma gondii infection associated with the occurrence of schizophrenia? A case-control study.
    PLoS One. 2022;17:e0270377.
    PubMed     Abstract available


  48. BARBIC D, Whyte M, Sidhu G, Luongo A, et al
    One-year mortality of emergency department patients with substance-induced psychosis.
    PLoS One. 2022;17:e0270307.
    PubMed     Abstract available


  49. CHIEN TY, Chern JS, Wang SP, Yang Y, et al
    Effects of multitask training on cognition and motor control in people with schizophrenia spectrum disorders.
    PLoS One. 2022;17:e0264745.
    PubMed     Abstract available


  50. YOSHIKAWA A, Kushima I, Miyashita M, Suzuki K, et al
    Exonic deletions in IMMP2L in schizophrenia with enhanced glycation stress subtype.
    PLoS One. 2022;17:e0270506.
    PubMed     Abstract available


  51. AKENA D, Semeere A, Kadama P, Mwesiga EK, et al
    Feasibility of conducting a pilot randomized control trial of a psycho-education intervention in patients with a first episode psychosis in Uganda-A study protocol.
    PLoS One. 2022;17:e0268493.
    PubMed     Abstract available


  52. GARGANO G, Caletti E, Perlini C, Turtulici N, et al
    Language production impairments in patients with a first episode of psychosis.
    PLoS One. 2022;17:e0272873.
    PubMed     Abstract available


  53. WYNN JK, McCleery A, Novacek DM, Reavis EA, et al
    The impact of the COVID-19 pandemic on mental health and functional outcomes in Veterans with psychosis or recent homelessness: A 15-month longitudinal study.
    PLoS One. 2022;17:e0273579.
    PubMed     Abstract available


  54. KHATTAK MI, Dikomitis L, Khan MF, Haq MU, et al
    Patients' and healthcare professionals' perspectives on a community-based intervention for schizophrenia in Pakistan: A focus group study.
    PLoS One. 2022;17:e0273286.
    PubMed     Abstract available


  55. KADRA-SCALZO G, Fonseca de Freitas D, Agbedjro D, Francis E, et al
    A predictor model of treatment resistance in schizophrenia using data from electronic health records.
    PLoS One. 2022;17:e0274864.
    PubMed     Abstract available


  56. AL-HAKEIM HK, Al-Musawi AF, Al-Mulla A, Al-Dujaili AH, et al
    The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis.
    PLoS One. 2022;17:e0275839.
    PubMed     Abstract available


  57. RAMOS-MASTACHE D, Mondragon-Maya A, Liemburg EJ, Enriquez-Geppert S, et al
    Understanding the relationship between apathy, cognition and functional outcome in schizophrenia: The significance of an ecological assessment.
    PLoS One. 2022;17:e0277047.
    PubMed     Abstract available


  58. JONES CJ, Hazell CM, Hayward M, Pandey A, et al
    Caring for Carers (C4C): Results from a feasibility randomised controlled trial of positive written disclosure for older adult carers of people with psychosis.
    PLoS One. 2022;17:e0277196.
    PubMed     Abstract available


  59. RAZZAK RA, Jahrami H, Husni M, Ali ME, et al
    Perceptual visual dependence for spatial orientation in patients with schizophrenia.
    PLoS One. 2022;17:e0278718.
    PubMed     Abstract available


  60. AL-NEMA M, Gaurav A, Lee MT, Okechukwu P, et al
    Evaluation of the acute oral toxicity and antipsychotic activity of a dual inhibitor of PDE1B and PDE10A in rat model of schizophrenia.
    PLoS One. 2022;17:e0278216.
    PubMed     Abstract available


  61. JOHNSON T, Saatci D, Handunnetthi L
    Maternal immune activation induces methylation changes in schizophrenia genes.
    PLoS One. 2022;17:e0278155.
    PubMed     Abstract available


  62. MATHIS WS, Ferrara M, Burke S, Hyun E, et al
    Granular analysis of pathways to care and durations of untreated psychosis: A marginal delay model.
    PLoS One. 2022;17:e0270234.
    PubMed     Abstract available


  63. SOLER-VIDAL J, Fuentes-Claramonte P, Salgado-Pineda P, Ramiro N, et al
    Brain correlates of speech perception in schizophrenia patients with and without auditory hallucinations.
    PLoS One. 2022;17:e0276975.
    PubMed     Abstract available


  64. VAN DER STOUWE ECD, de Vries B, Steenhuis LA, Waarheid CO, et al
    BEATVIC, a body-oriented resilience therapy for individuals with psychosis: Short term results of a multi-center RCT.
    PLoS One. 2022;17:e0279185.
    PubMed     Abstract available


    January 2021
  65. HINOJOSA-MARQUES L, Monsonet M, Kwapil TR, Barrantes-Vidal N, et al
    The impact of family environment on self-esteem and symptoms in early psychosis.
    PLoS One. 2021;16:e0249721.
    PubMed     Abstract available


  66. MAKI S, Nagai K, Ando S, Tamakoshi K, et al
    Structure and predictors of in-hospital nursing care leading to reduction in early readmission among patients with schizophrenia in Japan: A cross-sectional study.
    PLoS One. 2021;16:e0250771.
    PubMed     Abstract available


  67. WENG S, Wang B, Li M, Chao S, et al
    Genome-wide association study of antipsychotic-induced sinus bradycardia in Chinese schizophrenia patients.
    PLoS One. 2021;16:e0249997.
    PubMed     Abstract available


  68. HAYASHI N, Igarashi Y, Harima H
    Delusion progression process from the perspective of patients with psychoses: A descriptive study based on the primary delusion concept of Karl Jaspers.
    PLoS One. 2021;16:e0250766.
    PubMed     Abstract available


  69. ROSEN DL, Travers D
    Emergency department visits among patients transported by law enforcement officers.
    PLoS One. 2021;16:e0244679.
    PubMed     Abstract available


  70. KIM K, Duc NT, Choi M, Lee B, et al
    EEG microstate features for schizophrenia classification.
    PLoS One. 2021;16:e0251842.
    PubMed     Abstract available


  71. KRONBICHLER L, Stelzig-Scholer R, Lenger M, Weber S, et al
    Preserved intention understanding during moral judgments in schizophrenia.
    PLoS One. 2021;16:e0251180.
    PubMed     Abstract available


  72. LINCOLN SH, Johnson T, Kim S, Edenbaum E, et al
    Psychosis proneness, loneliness, and hallucinations in nonclinical individuals.
    PLoS One. 2021;16:e0251753.
    PubMed     Abstract available


  73. KOBORI A, Miyashita M, Miyano Y, Suzuki K, et al
    Advanced glycation end products and cognitive impairment in schizophrenia.
    PLoS One. 2021;16:e0251283.
    PubMed     Abstract available


  74. KURUKGY JL, Bourgin J, Benoit JP, Guessoum SB, et al
    Implementing organicity investigations in early psychosis: Spreading expertise.
    PLoS One. 2021;16:e0252610.
    PubMed     Abstract available


  75. NOROVSAMBUU O, Tsend-Ayush A, Lkhagvasuren N, Jav S, et al
    Main characteristics of dermatoglypics associated with schizophrenia and its clinical subtypes.
    PLoS One. 2021;16:e0252831.
    PubMed     Abstract available


  76. SCHILLING TM, Bossert M, Konig M, Wirtz G, et al
    Acute effects of a single dose of 2 mA of anodal transcranial direct current stimulation over the left dorsolateral prefrontal cortex on executive functions in patients with schizophrenia-A randomized controlled trial.
    PLoS One. 2021;16:e0254695.
    PubMed     Abstract available


  77. HUCKLE C, Lemmel F, Johnson S
    Experiences of friendships of young people with first-episode psychosis: A qualitative study.
    PLoS One. 2021;16:e0255469.
    PubMed     Abstract available


  78. SHOR O, Glik A, Yaniv-Rosenfeld A, Valevski A, et al
    EEG p-adic quantum potential accurately identifies depression, schizophrenia and cognitive decline.
    PLoS One. 2021;16:e0255529.
    PubMed     Abstract available


  79. JUNG YS, Kim YE, Go DS, Yoon SJ, et al
    The prevalence, incidence, and admission rate of diagnosed schizophrenia spectrum disorders in Korea, 2008-2017: A nationwide population-based study using claims big data analysis.
    PLoS One. 2021;16:e0256221.
    PubMed     Abstract available


  80. SHIMIZU J, Kuwata H, Kuwata K
    Differences in fractal patterns and characteristic periodicities between word salads and normal sentences: Interference of meaning and sound.
    PLoS One. 2021;16:e0247133.
    PubMed     Abstract available


  81. DUTRA-TAVARES AC, Manhaes AC, Semeao KA, Maia JG, et al
    Does nicotine exposure during adolescence modify the course of schizophrenia-like symptoms? Behavioral analysis in a phencyclidine-induced mice model.
    PLoS One. 2021;16:e0257986.
    PubMed     Abstract available


  82. MARTIN J, Asjadi K, Hubbard L, Kendall K, et al
    Examining sex differences in neurodevelopmental and psychiatric genetic risk in anxiety and depression.
    PLoS One. 2021;16:e0248254.
    PubMed     Abstract available


  83. DOYEN S, Taylor H, Nicholas P, Crawford L, et al
    Hollow-tree super: A directional and scalable approach for feature importance in boosted tree models.
    PLoS One. 2021;16:e0258658.
    PubMed     Abstract available


  84. DESALEGN D, Abdu Z, Hajure M
    Prevalence of tobacco dependence and associated factors among patients with schizophrenia attending their treatments at southwest Ethiopia; hospital-based cross-sectional study.
    PLoS One. 2021;16:e0261154.
    PubMed     Abstract available


  85. WOLDEKIDAN NA, Mohammed AS, Degu A, Tadiwos Y, et al
    Prevalence of metabolic syndrome and associated factors among psychiatric patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
    PLoS One. 2021;16:e0256195.
    PubMed     Abstract available


  86. SAKURAI K, Itou T, Morita M, Kasahara E, et al
    Effects of Importin alpha1/KPNA1 deletion and adolescent social isolation stress on psychiatric disorder-associated behaviors in mice.
    PLoS One. 2021;16:e0258364.
    PubMed     Abstract available


  87. ZANDER-SCHELLENBERG T, Kuhn SAK, Moller J, Meyer AH, et al
    Is intuition allied with jumping to conclusions in decision-making? An intensive longitudinal study in patients with delusions and in non-clinical individuals.
    PLoS One. 2021;16:e0261296.
    PubMed     Abstract available


  88. LEE GS, Zhang J, Wu Y, Zhou Y, et al
    14-3-3 proteins promote synaptic localization of N-methyl d-aspartate receptors (NMDARs) in mouse hippocampal and cortical neurons.
    PLoS One. 2021;16:e0261791.
    PubMed     Abstract available


  89. HAYAKAWA T, Terahara M, Fujito NT, Matsunaga T, et al
    Lower promoter activity of the ST8SIA2 gene has been favored in evolving human collective brains.
    PLoS One. 2021;16:e0259897.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.